Influenza A/H1N1 Severe Pneumonia: Novel Morphocytological Findings in Bronchoalveolar Lavage
Table 1
Demographics, comorbidities, severity on admission, clinical course, microbiological isolations, and outcome.
Patient 1
Patient 2
Patient 3
Age
51
43
24
Gender
Male
Female
Male
BMI
27
32
24
Immunosuppression
No
No
No
Comorbidities
Gout
Hypothyroidism, depression, chronic headache
None
SOFA score on admission
6
4
6
CURB-65 score on admission
0
1
2
Hospital day when MV was started
3rd
2nd
2nd
Hospital day when ECMO was started
7th
2nd
4th
Length of ECMO (days)
20
26
15
Hospital day when influenza virus assay was performed and oseltamivir started
3rd
2nd
1st
Length of oseltamivir therapy (days)
13
9
30
Nosocomial pathogens isolated
C. parapsilosis on throat specimen and S. epidermidis on BAS
P. aeruginosa MDR, C. albicans, C. glabrata, and C. parapsilosis on BAS
P. aeruginosa MDR, Flavobacterium, and C. indologenes on BAS
LP and SP urinary antigens
Negative
Negative
Negative
CP, MP, and LP IgM and IgG
Negative
Negative
Negative
Outcome
Alive
Alive
Alive
MV: mechanical ventilation; ECMO: extracorporeal membrane oxygenation; LP: L. pneumophila; SP: S. pneumoniae; CP: C. pneumoniae; MP: M. pneumoniae; BAS: bronchial aspirate; MDR: multidrug resistant (used for pathogens resistant to at least three drugs from different antibiotic categories).
